نتائج البحث - Hong Liu‐Seifert

  • يعرض 1 - 9 نتائج من 9
تنقيح النتائج
  1. 1
    Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

    Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs حسب Hong Liu‐Seifert, David H. Adams, Bruce J. Kinon

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee

    A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee حسب Amy S. Chappell, D. Desaiah, Hong Liu‐Seifert, Shuyu Zhang, Vladimir Skljarevski, Yuri Belenkov, Jacques P. Brown

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Assessing quality of life in Alzheimer's disease: Implications for clinical trials

    Assessing quality of life in Alzheimer's disease: Implications for clinical trials حسب Kristin Kahle‐Wrobleski, Wenyu Ye, David Henley, Ann Marie Hake, Eric Siemers, Yun‐Fei Chen, Hong Liu‐Seifert

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

    Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years حسب Hong Liu‐Seifert, Eric Siemers, Karen C. Holdridge, Scott W. Andersen, Ilya Lipkovich, Christopher Carlson, Gopalan Sethuraman, S. Hoog, Roza Hayduk, Rachelle S. Doody, Paul Aisen

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease

    Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease حسب Hong Liu‐Seifert, Eric Siemers, Karen Price, Baoguang Han, Katherine J. Selzler, David Henley, Karen Sundell, Paul Aisen, Jeffrey L. Cummings, Joel Raskin, Richard C. Mohs

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

    Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients حسب Eric Siemers, Karen Sundell, Christopher Carlson, Michael Case, Gopalan Sethuraman, Hong Liu‐Seifert, Sherie A. Dowsett, Michael J. Pontecorvo, Robert A. Dean, Ronald B. DeMattos

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

    A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, ope... حسب Philip J. Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu‐Seifert, Paul Emery, Sreekumar Pillai, Philip Helliwell

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

    Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease حسب Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Rema Raman, Xiaoying Sun, Paul Aisen, Eric Siemers, Hong Liu‐Seifert, Richard C. Mohs

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

    Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease حسب Lawrence S. Honig, Bruno Vellas, Mark Woodward, Merçé Boada, Roger Bullock, Michael Borrie, Klaus Häger, Niels Andreasen, Elio Scarpini, Hong Liu‐Seifert, Michael Case, Robert A. Dean, Ann Marie Hake, Karen Sundell, Vicki Poole Hoffmann, Christopher Carlson, Rashna Khanna, Mark A. Mintun, Ronald B. DeMattos, Katherine J. Selzler, Eric Siemers

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: